[en] Merkel cell carcinoma (MCC) is a rare and highly malignant skin cancer with neuroendocrine differentiation. We studied the potential value of 18FDG PET in the management of MCC. Eleven patients with MCC were examined by 18FDG PET and PET-CT for staging purpose (n=4) or for detection of recurrence (n=7). Qualitative and quantitative interpretation of PET studies was performed routinely. 18FDG PET observations were compared to clinical and radiological findings. In 6 patients, PET findings were also compared to histology. In 7 patients, the 18FDG tumor uptake was compared to the MCC proliferative activity expressed by the Ki-67 index. 18FDG PET was contributive in 10/11 MCC patients. In 7 patients, 18FDG PET detected focal lesions or a disseminated stage of the disease including dermal, nodal and visceral metastases. In 3 patients, a normal 18FDG PET confirmed complete remission of disease. Most MCC patients exhibited highly 18FDG-avid sites suggestive of increased glucose metabolism. This imaging pattern was related to a high proliferative activity (Ki-67 index >50%). In 1 patient with a weakly proliferative nodal MCC (Ki-67<10%), a false negative result was yielded by metabolic imaging. In 4/11 patients, 18FDG PET revealed an unsuspected second neoplasm in addition to MCC. It is concluded that whole-body 18FDG PET may be useful in the management of MCC patients. However, a normal 18FDG PET aspect cannot rule out MCC with low proliferative activity.
Disciplines :
Dermatology Oncology
Author, co-author :
Belhocine, Tarik; Centre Hospitalier Universitaire de Liège - CHU > Departments of Nuclear Medicine
Pierard, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie
Frühling, Janos; Jules Bordet Cancer Institute, Bruxelles, Belgium > Departments of Nuclear Medicine
Letesson, Gaëtan
Bolle, Stéphanie
Hustinx, Roland ; Centre Hospitalier Universitaire de Liège - CHU > Médecine nucléaire
Dargent, Jean-Louis
Flamen, Patrick; Departments of Nuclear Medicine
Rigo, Pierre ; Hôpital Princesse Grace 3, Monte Carlo, Monaco
Language :
English
Title :
Clinical added-value of 18FDG PET in neuroendocrine-merkel cell carcinoma
Yiengpruksawan A, Coit DG, Thaler HT, Urmacher C and Knapper WK: Merkel cell carcinoma. Prognosis and management. Arch Surg 126: 1514-1519, 1991.
Hitchcock CL, Bland KI, Laney RG III, Franzini D, Harris B and Copeland EM III: Neuroendocrine (Merkel cell) carcinoma of the skin: its natural history, diagnosis and treatment. Ann Surg 207: 669-683, 1988.
Mott RT, Smoller BR and Morgan MB: Merkel cell carcinoma: a clinicopathologic study with prognostic implications. J Cutan Pathol 31: 217-223, 2004. (Pubitemid 38230563)
Shaw JHG and Rumball E: Merkell cell tumor: clinical behavior and treatment. Br J Surg 78: 138-142, 1991.
Wasserberg N, Schachter J, Fenig E, Feinmesser M and Gutman H: Applicability of the sentinel node technique to Merkel cell carcinoma. Dermatol Surg 26: 134-138, 2000.
Medina-Franco H, Urist MM, Fiveash J, Heslin MJ, Bland KI and Beenken SW: Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol 8: 204-208, 2001. (Pubitemid 32294799)
Poulsen M: Merkel-cell carcinoma of the skin. Lancet Oncol 5: 593-599, 2004.
Nguyen B and McCullough AE: Imaging of Merkel cell carcinoma. Radiographics 22: 367-376, 2002.
Kwekkeboom DJ, Hoff AM, Lamberts SW, Oei HY and Krenning EP: Somatostatin analogue scintigraphy: a simple and sensitive method for the in vivo visualization of Merkel cell tumors and their metastases. Arch Dermatol 128: 818-821, 1992.
Delbeke D: Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med 40: 591-603, 1999.
Lampreave JL, Benard F, Alavi A, Jimenez-Hoyuela J and Fraker D: PET evaluation of therapeutic limb perfusion in Merkel's cell carcinoma. J Nucl Med 39: 2087-2090, 1998. (Pubitemid 29001795)
Wong CO, Pham AN and Dworkin HJ: F-18 FDG accumulation in an octreotide negative Merkel cell tumor. Clin Positron Imaging 3: 71, 2000.
Nguyen BD: Positron emission tomographic imaging of Merkel cell carcinoma. Clin Nucl Med 27: 922-923, 2002.
Lin O, Thomas A, Singh A and Greenspan B: Complementary role of positron emission tomography in Merkel cell carcinoma. South Med J 97: 1110-1112, 2004. (Pubitemid 39518706)
Scanga DR, Martin WH and Delbeke D: Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine and neural crest tumors. Clin Nucl Med 29: 86-90, 2004. (Pubitemid 38240735)
Yao M, Smith RB, Hoffman HT, Funk GF, Graham MM and Buatti JM: Merkel cell carcinoma: two case reports focusing on the role of fluorodeoxyglucose positron emission tomography imaging in staging and surveillance. Am J Clin Oncol 28: 205-210, 2005.
Golan H, Volkov O, Linchinsky O and Melloul M: FDG-PET imaging in Merkel cell carcinoma - value of head-to-toe scan. Nucl Med Rev Cent East Eur 8: 135-136, 2005. (Pubitemid 43115966)
Pasquali C, Rubello D, Sperti C, Gasparoni P, Liessi G, Chierichetti F, Ferlin G and Pedrazzoli S: Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 22: 588-592, 1998. (Pubitemid 28215437)
Adams S, Baum RP, Hertel A, Schumm-Drager PM, Usadel KH and Hor G: Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumors: comparison with the expression of the Ki-67 antigen. Nucl Med Commun 19: 641-647, 1998. (Pubitemid 28368315)
Belhocine T, Foidart J, Rigo P, Najjar F, Thiry A, Quatresooz P and Hustinx R: FDG-PET and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumors: correlations with the pathological indexes P53 and Ki-67. Nucl Med Commun 23: 727-734, 2002. (Pubitemid 34837002)
Skelton HG, Smith KJ, Hitchcock CL, McCarthy WF, Lupton GP and Graham JH: Merkel cell carcinoma: analysis of clinical, histologic and immunohistologic features of 132 cases with relation to survival. J Am Acad Dermatol 37: 734-739, 1997. (Pubitemid 27500317)
Larcos G and Maisey MN: FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nucl Med Commun 17: 197-198, 1996. (Pubitemid 26101305)
Brenner B, Sulkes A, Rakowsky E, Feinmesser M, Yukelson A, Bar-Haim E, Katz A, Idelevich E, Neuman A, Barhana M and Fenig E: Second neoplasms in patients with Merkel cell carcinoma. Cancer 91: 1358-1362, 2001. (Pubitemid 32267048)
Gooptu C, Woolons A, Ross J, Price M, Wojnarowska F, Morris PJ, Wall S and Bunker CB: Merkel cell carcinoma arising after therapeutic immunosuppression. Br J Dermatol 137: 637-641, 1997. (Pubitemid 27469522)
Talbot JN, Kerrou K, Missoum F, Grahek D, Aide N, Lumbroso J and Montravers F: 6-F-18Fluoro-L-DOPA Positron emission tomography in the imaging of merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2-f-18fluoro-d-glucose positron emission tomography or pentetreotide-111 inspect data. Mol Imaging Biol 5: 1-5, 2005.
Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K and Coit DG: Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol 23: 2300-2309, 2005. (Pubitemid 46218722)
